Adronil Tablets 150Mg (1 Box = 1 Tablet)

Requires Prescription (YES/NO)

Yes

Generics

Ibandronate sodium

Used For

Osteoporosis

How it works

The action of Ibandronate on bone tissue is based on its affinity for hydroxyapatite, part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Dosage

Ibandronate sodium

Side Effects

Vascular Disorders : Hnoisnetrepy , Gastrointestinal Disorders : Dyspepsia , Nausea , Diarrhea , Constipation , Abdominal Pain , Musculoskeletal and Connective Tissue Disorders : Arthralgia , Back Pain, Pain in Extremity , Localized Osteoarthritis , Myalgia , Muscle Cramp , Nervous System Disorders : Headache , Dizziness , General Disorders and Administration Site Conditions : Influenza-like Illness , Skin and Subcutaneous Tissue Disorders : Rash , Psychiatric Disorders : Insomnia.

Drug Interactions

Calcium Supplements/Antacids : : Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) , Aspirin, NSAIDs, and bisphosphonates

Indication

Ibandronic Acid is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

When not to Use

Known hypersensitivity to Ibandronic Acid or to any of its excipients, Hypocalcemia, Inability to stand or sit upright for at least 60 minutes.

Precaution

Ibandronic Acid like other bisphosphonates administered orally, may cause upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer. Advise patients to comply with the dosing instructions to minimize the risk of these effects. Discontinue use if new or worsening symptoms develop.

Warning 1

Treat hypocalcemia and other disturbances of bone and mineral metabolism before starting Ibandronic Acid therapy. Adequate intake of calcium and vitamin D is important in all patients to prevent hypocalcemia.

Warning 2

Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Ibandronic Acid and other bisphosphonates. The time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. Consider discontinuing use if severe symptoms develop.

Warning 3

Osteonecrosis, primarily in the jaw, has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g., anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw (ONJ) while on bisphosphonate therapy, dental surgery may exacerbate the condition.

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.